A 62-year-old woman presents with a 3-year history of progressive pain and stiffness in both knees, worse in the morning and after activity. Physical examination reveals bony enlargement of the knees, crepitus on movement, and mild varus deformity. Plain radiographs show joint space narrowing, osteophytes, and subchondral sclerosis bilaterally. She has tried paracetamol 500 mg thrice daily for 2 weeks with minimal relief. What is the most appropriate next step in management?

Explanation

## Management Approach to Symptomatic Osteoarthritis **Key Point:** The stepwise management of osteoarthritis follows a pyramid: non-pharmacological → pharmacological (simple analgesics optimized → NSAIDs) → intra-articular injections → surgical intervention. Before escalating to oral NSAIDs, guidelines recommend optimizing the current analgesic regimen first. ### Why Increasing Paracetamol to Maximum Dose + Topical NSAIDs is Correct This patient has been on **subtherapeutic paracetamol** (500 mg TDS = 1.5 g/day) — well below the recommended maximum of 4 g/day (or 3 g/day in elderly). The appropriate next step per EULAR, OARSI, and NICE guidelines is to **optimize the existing analgesic** before escalating to oral NSAIDs. Topical NSAIDs (e.g., diclofenac gel) are also guideline-recommended as an adjunct with a favorable safety profile, particularly in patients ≥60 years where systemic NSAID risks (GI, cardiovascular, renal) are significant. **High-Yield:** NICE (2022) and OARSI guidelines recommend paracetamol at maximum tolerated dose as the first oral analgesic for OA. Topical NSAIDs are preferred over oral NSAIDs in older patients due to equivalent local efficacy with minimal systemic absorption. **Clinical Pearl:** Oral NSAIDs are the next step only after adequate trials of both optimized paracetamol AND topical NSAIDs have failed. In a 62-year-old woman, the GI and cardiovascular risks of oral NSAIDs (especially indomethacin, which has the highest GI toxicity among NSAIDs) must be carefully weighed. ### Management Pyramid for Osteoarthritis ```mermaid flowchart TD A[Symptomatic OA]:::outcome --> B{Adequate trial of simple analgesics at max dose?}:::decision B -->|No| C[Optimize Paracetamol to 4g/day + Topical NSAIDs + Physiotherapy]:::action B -->|Yes| D{Pain controlled?}:::decision D -->|Yes| E[Continue + Exercise/Weight management]:::action D -->|No| F[Add oral NSAIDs + PPI + Physiotherapy]:::action F --> G{Adequate response?}:::decision G -->|Yes| H[Maintain therapy]:::action G -->|No| I[Intra-articular injections → Arthroplasty]:::action ``` ### Comparison of Analgesic Options | Agent | Efficacy in OA | GI Risk | CV Risk | Use in This Case | |-------|---|---|---|---| | Paracetamol (optimized) | Modest | Minimal | None | **First — not yet maximized** | | Topical NSAIDs | Mild–moderate | Minimal | None | **Adjunct — appropriate now** | | Oral NSAIDs | High | Moderate–high (age 62) | Moderate | Premature — skip to this step | | COX-2 inhibitors | High | Minimal GI | Moderate CV | Alternative if GI intolerance | ### Why Option C (Oral NSAIDs) is Premature Jumping to oral NSAIDs before optimizing paracetamol violates the stepwise approach endorsed by EULAR (2019), OARSI (2019), and NICE (2022). Indomethacin in particular carries the **highest GI toxicity** among NSAIDs and is generally avoided as a first-choice NSAID in elderly patients. Oral NSAIDs are appropriate only after failure of optimized paracetamol and topical NSAIDs. ### Why Surgery is Not Yet Indicated Arthroscopic debridement has **no proven benefit** in OA (AAOS, EULAR). Total knee arthroplasty is reserved for severe, refractory OA with significant functional impairment after exhausting conservative management. **Reference:** EULAR recommendations for the management of knee osteoarthritis (2019); NICE guideline NG226 (2022); Harrison's Principles of Internal Medicine, 21st ed.